Hormonal

Tirzepatide use is associated with a significantly higher incidence of gastrointestinal adverse events, specifically nausea, vomiting, and diarrhea, compared to placebo, although serious adverse event rates remain comparable.

Expect gastrointestinal side effects when starting tirzepatide. Nausea, vomiting, and diarrhea are significantly more common than with a placebo, particularly when starting or increasing the dose. However, these are typically mild to moderate and do not appear to increase the risk of serious health events. Most patients tolerate the medication well enough to continue treatment, which is necessary to achieve the significant weight loss benefits.